These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 34254271)
1. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder. Parlier-Ahmad AB; Pugh M; Martin CE J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271 [TBL] [Abstract][Full Text] [Related]
2. Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender. Parlier-Ahmad AB; Radic M; Svikis DS; Martin CE Drug Alcohol Depend; 2022 Mar; 232():109337. PubMed ID: 35123364 [TBL] [Abstract][Full Text] [Related]
3. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. Mauro PM; Gutkind S; Annunziato EM; Samples H JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762 [TBL] [Abstract][Full Text] [Related]
4. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails. Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354 [TBL] [Abstract][Full Text] [Related]
5. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Rhee TG; Rosenheck RA Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA; Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068 [TBL] [Abstract][Full Text] [Related]
7. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants. Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246 [No Abstract] [Full Text] [Related]
8. Impact of Perceived Access and Treatment Knowledge on Medication Preferences for Opioid Use Disorder. Jaffe K; Patel S; Chen L; Slat S; Bohnert A; Lagisetty P Subst Use Addctn J; 2024 Oct; 45(4):706-715. PubMed ID: 38828548 [TBL] [Abstract][Full Text] [Related]
9. Recovery capital among people receiving treatment for opioid use disorder with buprenorphine. Parlier-Ahmad AB; Terplan M; Svikis DS; Ellis L; Martin CE Harm Reduct J; 2021 Oct; 18(1):103. PubMed ID: 34645477 [TBL] [Abstract][Full Text] [Related]
10. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386 [TBL] [Abstract][Full Text] [Related]
11. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults. Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589 [TBL] [Abstract][Full Text] [Related]
12. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701 [TBL] [Abstract][Full Text] [Related]
13. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder. Pytell JD; Sklar MD; Carrese J; Rastegar DA; Gunn C; Chander G J Gen Intern Med; 2022 Feb; 37(3):593-600. PubMed ID: 34027611 [TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575 [TBL] [Abstract][Full Text] [Related]
15. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697 [TBL] [Abstract][Full Text] [Related]
16. Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder. White AM; Eglovitch M; Parlier-Ahmad AB; Dzierzewski JM; James M; Bjork JM; Moeller FG; Martin CE PLoS One; 2024; 19(6):e0304461. PubMed ID: 38870144 [TBL] [Abstract][Full Text] [Related]
17. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362 [TBL] [Abstract][Full Text] [Related]
18. Interpersonal Trauma Among Women and Men Receiving Buprenorphine in Outpatient Treatment for Opioid Use Disorder. Martin CE; Parlier-Ahmad AB; Beck L; Thomson ND Violence Against Women; 2022 Aug; 28(10):2448-2465. PubMed ID: 34894888 [TBL] [Abstract][Full Text] [Related]
19. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic. Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256 [TBL] [Abstract][Full Text] [Related]
20. Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder. Cook RR; Jaworski EN; Hoffman KA; Waddell EN; Myers R; Korthuis PT; Vergara-Rodriguez P Subst Abus; 2023 Oct; 44(4):301-312. PubMed ID: 37842910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]